An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...

Sanofi India, Schaeffler India share prices will remain in focus on Thursday as will declare dividend today. The meeting of ...

Even as President Donald Trump wages a very public fight against diversity, equity and inclusion (DEI) initiatives in the ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...